Functional polymorphism -31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among Chinese

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Ma, Fuchao ^a,b   Zhang, Hongxing ^a   Zhai, Yun ^a   Huang, Wenfeng ^a,b   Zhao, Chang ^b   Ou, Shengqiu ^b   Zhou, Hong ^b   Yuan, Wenzhao ^b   Wang, Zhifu ^a   Wang, Hongxue ^a,b   Yue, Wei ^a   Yu, Lixia ^a   Li, Peiyao ^a   Xia, Xia ^a   Cai, Mi ^a   Zhang, Yang ^a   Cui, Ying ^b   He, Fuchu ^a,c   Ma, Yilong ^b   Zhou, Gangqiao ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CHINA; CHINESE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; POPULATION BASED CASE CONTROL STUDY; PROMOTER REGION; RISK FACTOR; ASIAN; CASE CONTROL STUDY; DISEASE COURSE; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; METASTASIS; MIDDLE AGED; NASOPHARYNX TUMOR; PATHOLOGY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 79751517801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016748     Document Type: Article

References (37)

1. Wei WI, Sham JS (2005) Nasopharyngeal carcinoma. Lancet 365: 2041-2054.
2. Chang ET, Adami HO (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1765-1777.
3. Zhou G, Zhai Y, Cui Y, Qiu W, Yang H, et al. (2007) Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma. Hum Mutat 28: 1091-1097.
4. Zhou G, Zhai Y, Cui Y, Zhang X, Dong X, et al. (2007) MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 13: 2627-2633.
5. He Y, Zhou G, Zhai Y, Dong X, Lv L, et al. (2005) Association of PLUNC gene polymorphisms with susceptibility to nasopharyngeal carcinoma in a Chinese population. J Med Genet 42: 172-176.
6. Jalbout M, Bouaouina N, Gargouri J, Corbex M, Ben AS, et al. (2003) Polymorphism of the stress protein HSP70-2 gene is associated with the susceptibility to the nasopharyngeal carcinoma. Cancer Lett 193: 75-81.
7. Goldsmith DB, West TM, Morton R (2002) HLA associations with nasopharyngeal carcinoma in Southern Chinese: a meta-analysis. Clin Otolaryngol Allied Sci 27: 61-67.
8. Deng L, Zhao XR, Pan KF, Wang Y, Deng XY, et al. (2002) Cyclin D1 polymorphism and the susceptibility to NPC using DHPLC. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 34: 16-20.
9. Nazar-Stewart V, Vaughan TL, Burt RD, Chen C, Berwick M, et al. (1999) Glutathione S-transferase M1 and susceptibility to nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 8: 547-551.
10. Cho WC (2010) Most common cancers in Asia-Pacific region: nasopharyngeal carcinoma. In: Cancer report of Asian-Pacific region 2010 Asian Pacific Organization for Cancer Prevention. pp 284-289.
11. Cho WC (2010) Recent progress in genetic variants associated with cancer and their implications in diagnostics development. Expert Rev Mol Diagn 10: 699-703.
12. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, et al. (2010) A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 42: 599-603.
13. Zhou B, Rao L, Li Y, Gao L, Wang Y, et al. (2009) A functional insertion/ deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett 275: 72-76.
14. Nong LG, Luo B, Zhang L, Nong HB (2009) Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol 28: 507-513.
15. Melet A, Song K, Bucur O, Jagani Z, Grassian AR, et al. (2008) Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol 615: 47-79.
16. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
17. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54.
18. Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, et al. (2007) Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 204: 1603-1611.
19. Jiang Y, de Bruin A, Caldas H, Fangusaro J, Hayes J, et al. (2005) Essential role for survivin in early brain development. J Neurosci 25: 6962-6970.
20. Xing Z, Conway EM, Kang C, Winoto A (2004) Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 199: 69-80.
21. Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, et al. (2004) Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 199: 399-410.
22. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
23. Li YH, Hu CF, Shao Q, Huang MY, Hou JH, et al. (2008) Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 6: 1.
24. Shi W, Bastianutto C, Li A, Perez-Ordonez B, Ng R, et al. (2006) Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer 119: 2467-2475.
25. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, et al. (2006) Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 12: 5726-5732.
26. Faqing T, Zhi H, Liqun Y, Min T, Huanhua G, et al. (2005) Epstein-Barr virus LMP1 initiates cell proliferation and apoptosis inhibition via regulating expression of Survivin in nasopharyngeal carcinoma. Exp Oncol 27: 96-101.
27. Li F, Altieri DC (1999) Transcriptional analysis of human survivin gene expression. Biochem J 344 Pt 2: 305-311.
28. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, et al. (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60: 31-39.
29. Xu Y, Fang F, Ludewig G, Jones G, Jones D (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23: 527-537.
30. Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, et al. (2009) Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 24: 145-150.
31. Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, et al. (2009) Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 73: 670-674.
32. Cheng ZJ, Hu LH, Huang SJ (2008) [Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma]. Ai Zheng 27: 258-263.
33. Fleming ID, Cooper JS, Henson (1997) AJCC cancer staging manual.5th ed. Philadelphia: Lippincott-Raven.
34. Adams MJ, Khoury MJ, James LM (1989) The use of attributable fraction in the design and interpretation of epidemiologic studies. J Clin Epidemiol 42: 659-662.
35. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
36. Reed JC (2001) The Survivin saga goes in vivo. J Clin Invest 108: 965-969.
37. Yang L, Zhu H, Zhou B, Gu H, Yan H, et al. (2009) The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 54: 1021-1028.